MenüForum-NavigationForumMitgliederAnmeldenRegistrierenForum-Breadcrumbs - Du bist hier:ForumFlohmarkt: AllgemeineskmqacaAntwortenAntworten: kmqaca <blockquote><div class="quotetitle">Zitat von Gast am 25. März 2026, 10:29 Uhr</div>[url=https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord ]Zoya Demidenko[/url]: Scientist in Cancer Studies [url=https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2005.03.012 ]Zoya Demidenko[/url] is a distinguished investigator connected with the Department of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, New York. Before that, she conducted research at the National Institutes of Health and New York Medical College, establishing a robust background in life science study. Her academic contributions spans multiple pivotal areas, encompassing the PI3K/AKT/mTOR molecular pathway, cellular cycle regulation, cell senescence, and malignancy science. As of now, she has written over 46 academic publications, which have received more than 4,100 mentions — a indicator to the significance of her findings. Among her most significant discoveries lies in understanding the pathways of cellular senescence. Her studies demonstrated that when the cell cycle is halted while cellular expansion proceeds, the cells undergo senescence. Significantly, [url=https://www.researchgate.net/scientific-contributions/Zoya-N-Demidenko-39445053 ]Zoya Demidenko[/url] demonstrated that this shift is controlled with drugs using compounds such as mTOR inhibitors. [url=https://www.instagram.com/hibou_sova/ ]Zoya Demidenko[/url] has also contributed considerably to cancer treatment investigation, especially in the domain of cyclotherapy — a strategy intended to safeguarding normal cells from anticancer drugs while leaving cancer cells exposed. This approach carries significant potential for diminishing the side effects of oncological therapy. Throughout her professional journey, Demidenko has worked with leading investigators globally, including Dr. Mikhail Blagosklonny. Her publications appears in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. Possessing an h-index of 33, [url=https://pubmed.ncbi.nlm.nih.gov/22228887/ ]Zoya Demidenko[/url] ranks as a widely cited contributor in current biomedical research, whose findings keep to influence our knowledge of how cells age, respond to treatment, and how malignant disease can be better combated. https://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0026126 </blockquote><br> Abbrechen
